BeyondSpring Inc

BeyondSpring Inc. a clinical stage biopharmaceutical company together with its subsidiaries focuses on the development of cancer therapies. The company's lead asset is the Plinabulin a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents including nivolumab a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York New York.